Caribou Biosciences Share Price Today: Live Updates & Key Insights

Caribou Biosciences share price today is $1.88, up -5.08%. The stock opened at $1.97 against the previous close of $1.97, with an intraday high of $1.97 and low of $1.86.

Caribou Biosciences Share Price Chart

Caribou Biosciences

us-stock
To Invest in {{usstockname}}
us-stock

Caribou Biosciences Share Price Performance

$1.88 -0.0508(-5.08%) CRBU at 23 Mar 2026 12:33 PM Biotechnology
Lowest Today 1.86
Highest Today 1.97
Today’s Open 1.97
Prev. Close 1.97
52 Week High 3.54
52 Week Low 0.66
Day’s Range: Low 1.86 High 1.97
52-Week Range: Low 0.66 High 3.54
1 day return -
1 Week return +0.26
1 month return -3.11
3 month return +8.11
6 month return -3.61
1 year return +81.95
3 year return -57.02
5 year return -88.79
10 year return -

Caribou Biosciences Institutional Holdings

Pfizer Inc 4.85

Vanguard Group Inc 4.45

Vanguard Total Stock Mkt Idx Inv 2.82

Kynam Capital Management, LP 2.59

ACATIS Datini Valueflex Fonds A 2.07

Selectra J. Lamarck Biotech A 1.71

Renaissance Technologies Corp 1.70

BlackRock Inc 1.51

Aberdeen Group PLC 1.44

Partner Fund Management LP 1.41

abrdn Life Sciences Investors 1.25

Two Sigma Advisers, LLC 1.15

Bank of America Corp 1.11

Susquehanna International Group, LLP 1.07

Two Sigma Investments LLC 1.06

Dimensional Fund Advisors, Inc. 1.04

Geode Capital Management, LLC 1.01

Vanguard Institutional Extnd Mkt Idx Tr 0.96

Marshall Wace Asset Management Ltd 0.91

Jacobs Levy Equity Management, Inc. 0.85

Millennium Management LLC 0.79

FMR Inc 0.75

Maverick Capital Ltd 0.68

iShares Biotechnology ETF 0.64

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.60

Royal Bank of Canada 0.59

Schwab US Small-Cap ETF™ 0.45

Fidelity Extended Market Index 0.36

Bruce 0.26

AXS Green Alpha ETF 0.22

Blackrock Extended Mkt Fund CF 0.21

Extended Equity Market Fund K 0.18

DFA US Small Cap I 0.18

Fidelity Total Market Index 0.15

Bridgeway Ultra-Small Company Market 0.13

Fidelity Series Total Market Index 0.13

Spartan Extended Market Index Pool F 0.12

Avantis US Small Cap Equity ETF 0.12

NT Ext Equity Mkt Idx Fd - L 0.11

Northern Trust Extended Eq Market Idx 0.10

Caribou Biosciences Market Status

Strong Buy: 5

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Caribou Biosciences Fundamentals

Market Cap 180.71 M

PB Ratio 1.4752

PE Ratio 0.0

Enterprise Value 68.12 M

Total Assets 175.37 M

Volume 958720

Caribou Biosciences Company Financials

Annual Revenue FY23:34611000 34.6M, FY22:13851000 13.9M, FY21:9598000 9.6M, FY20:12361000 12.4M, FY19:5788000 5.8M

Annual Profit FY23:null 0.0M, FY22:13851000 13.9M, FY21:9598000 9.6M, FY20:12361000 12.4M, FY19:5788000 5.8M

Annual Net worth FY23:-94554000 -94.6M, FY22:-99421000 -99.4M, FY21:-66923000 -66.9M, FY20:-34308000 -34.3M, FY19:-23431000 -23.4M

Quarterly Revenue Q3/2025:2198000 2.2M, Q2/2025:2667000 2.7M, Q1/2025:2353000 2.4M, Q3/2024:2024000 2.0M, Q2/2024:3464000 3.5M

Quarterly Profit Q3/2025:1567000 1.6M, Q2/2025:2667000 2.7M, Q1/2025:2353000 2.4M, Q3/2024:2024000 2.0M, Q2/2024:2608000 2.6M

Quarterly Net worth Q3/2025:-27548000 -27.5M, Q2/2025:-54098000 -54.1M, Q1/2025:-39991000 -40.0M, Q3/2024:-34684000 -34.7M, Q2/2024:-37697000 -37.7M

About Caribou Biosciences & investment objective

Company Information Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Organisation Biotechnology

Employees 97

Industry Biotechnology

CEO Dr. Rachel E. Haurwitz Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Caribou Biosciences FAQs

What is the share price of Caribou Biosciences today?

The current share price of Caribou Biosciences is $1.88.

Can I buy Caribou Biosciences shares in India?

Yes, Indian investors can buy Caribou Biosciences shares by opening an international trading and demat account with Motilal Oswal.

How to buy Caribou Biosciences shares in India?

You can easily invest in Caribou Biosciences shares from India by:

Can I buy fractional shares of Caribou Biosciences?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Caribou Biosciences?

Caribou Biosciences has a market cap of $180.71 M.

In which sector does Caribou Biosciences belong?

Caribou Biosciences operates in the Biotechnology sector.

What documents are required to invest in Caribou Biosciences stocks?

To invest, you typically need:

What is the PE and PB ratio of Caribou Biosciences?

The PE ratio of Caribou Biosciences is N/A and the PB ratio is 1.48.